Always private
DuckDuckGo never tracks your searches.
Learn More
You can hide this reminder in Search Settings
All regions
Argentina
Australia
Austria
Belgium (fr)
Belgium (nl)
Brazil
Bulgaria
Canada (en)
Canada (fr)
Catalonia
Chile
China
Colombia
Croatia
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India (en)
Indonesia (en)
Ireland
Israel (en)
Italy
Japan
Korea
Latvia
Lithuania
Malaysia (en)
Mexico
Netherlands
New Zealand
Norway
Pakistan (en)
Peru
Philippines (en)
Poland
Portugal
Romania
Russia
Saudi Arabia
Singapore
Slovakia
Slovenia
South Africa
Spain (ca)
Spain (es)
Sweden
Switzerland (de)
Switzerland (fr)
Taiwan
Thailand (en)
Turkey
Ukraine
United Kingdom
US (English)
US (Spanish)
Vietnam (en)
Safe search: moderate
Strict
Moderate
Off
Any time
Any time
Past day
Past week
Past month
Past year
  1. Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have reported positive topline data from Hengrui's Phase II obesity trial, considering an 8mg dose of the companies' GLP-1/GIP receptor ...
  2. ropesgray.com

    Oct 10, 2024Ropes & Gray advised Kailera Therapeutics, Inc. and its investors on the establishment of the company, its $400 million Series A financing, and the worldwide (ex-China) licensing by the company of a portfolio of clinical-stage metabolic disease assets from Hengrui Pharmaceuticals, a leading Chinese pharmaceutical company.
  3. morganlewis.com

    Oct 10, 2024In May 2024, Hengrui Pharmaceutical, a leading global pharmaceutical company listed on the Shanghai Stock Exchange (600276.SH), announced that it had granted exclusive rights to develop, manufacture, and commercialize its proprietary GLP-1 class of drugs—HRS-7535, HRS-9531, and HRS-4729—to Hercules. ... now renamed Kailera Therapeutics ...
  4. Oct 1, 2024Kailera Therapeutics launched on Tuesday as the latest startup seeking a slice of the booming market for anti-obesity therapies with a rare $400 million in early-stage funding.
  5. synapse.patsnap.com

    May 20, 2024For Hengrui Pharmaceutical, the recent developments have been a mix of highs and lows.. On the evening of the 16th, Hengrui announced a collaboration deal: granting Hercules Pharmaceuticals (USA) the global rights outside of Greater China for the development, production, and commercialization of its GLP-1 combination. Hence, Hengrui will receive a $100 million milestone payment and is eligible ...
  6. Can’t find what you’re looking for?

    Help us improve DuckDuckGo searches with your feedback

Custom date rangeX